BROGLIO, Fabio
 Distribuzione geografica
Continente #
NA - Nord America 8.774
EU - Europa 5.818
AS - Asia 3.427
SA - Sud America 339
OC - Oceania 160
AF - Africa 47
Continente sconosciuto - Info sul continente non disponibili 5
Totale 18.570
Nazione #
US - Stati Uniti d'America 8.487
CN - Cina 1.423
IT - Italia 879
DE - Germania 690
IE - Irlanda 663
UA - Ucraina 661
SG - Singapore 609
FR - Francia 544
SE - Svezia 538
GB - Regno Unito 419
FI - Finlandia 403
KR - Corea 392
BR - Brasile 229
PL - Polonia 219
CA - Canada 207
JP - Giappone 207
AT - Austria 200
AU - Australia 142
ES - Italia 137
VN - Vietnam 130
IN - India 102
NL - Olanda 101
TR - Turchia 100
ID - Indonesia 85
RU - Federazione Russa 78
BE - Belgio 66
HK - Hong Kong 63
MX - Messico 62
PH - Filippine 54
TW - Taiwan 45
IL - Israele 39
CL - Cile 36
MY - Malesia 35
PT - Portogallo 34
AR - Argentina 31
CH - Svizzera 30
GR - Grecia 28
DK - Danimarca 26
HU - Ungheria 23
JO - Giordania 22
RO - Romania 22
IR - Iran 20
TH - Thailandia 19
CO - Colombia 18
NZ - Nuova Zelanda 18
UZ - Uzbekistan 16
NO - Norvegia 14
PE - Perù 13
EG - Egitto 12
SN - Senegal 12
LB - Libano 9
QA - Qatar 8
RS - Serbia 8
SA - Arabia Saudita 7
SI - Slovenia 7
CZ - Repubblica Ceca 6
IQ - Iraq 6
PK - Pakistan 6
ZA - Sudafrica 6
CY - Cipro 5
EU - Europa 5
BG - Bulgaria 4
GE - Georgia 4
GT - Guatemala 4
LT - Lituania 4
MA - Marocco 4
PY - Paraguay 4
AE - Emirati Arabi Uniti 3
AN - Antille olandesi 3
BD - Bangladesh 3
EC - Ecuador 3
EE - Estonia 3
KZ - Kazakistan 3
MK - Macedonia 3
SC - Seychelles 3
TN - Tunisia 3
UY - Uruguay 3
AZ - Azerbaigian 2
BH - Bahrain 2
DO - Repubblica Dominicana 2
HN - Honduras 2
IS - Islanda 2
LK - Sri Lanka 2
MU - Mauritius 2
MV - Maldive 2
NG - Nigeria 2
NP - Nepal 2
PR - Porto Rico 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
AL - Albania 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
CU - Cuba 1
DZ - Algeria 1
ET - Etiopia 1
JM - Giamaica 1
Totale 18.566
Città #
Beijing 1.005
Chandler 885
Dublin 647
Santa Clara 641
Singapore 483
Houston 451
Jacksonville 367
Villeurbanne 352
Fairfield 288
Redwood City 246
Dearborn 228
Ann Arbor 221
Princeton 214
Medford 213
Ashburn 208
Wilmington 199
Columbus 188
Nyköping 188
Vienna 188
Warsaw 175
Torino 144
Milan 128
Woodbridge 126
Boston 120
Seattle 113
Cambridge 107
Fremont 83
Boardman 71
Pisa 68
Dong Ket 67
Turin 64
Toronto 63
Verona 60
Jakarta 49
Tokyo 39
Norwalk 38
Nanjing 37
São Paulo 37
Guangzhou 35
Shanghai 35
Brussels 33
Lachine 31
London 31
New York 31
Hefei 27
Mountain View 26
Taipei 26
Ankara 24
Munich 24
Washington 24
Falls Church 23
Santiago 23
Sydney 20
Amsterdam 19
Istanbul 19
San Diego 19
Detroit 18
Menlo Park 17
San Mateo 17
Seoul 17
Cupertino 16
Duncan 16
Frankfurt am Main 16
Helsinki 16
Melbourne 16
Rome 16
Central District 15
Hangzhou 15
Jinan 15
Los Angeles 15
Moscow 15
Zhengzhou 15
Berlin 14
Buenos Aires 14
Kuala Lumpur 14
Absecon 13
Düsseldorf 13
Ottawa 13
Birmingham 12
Central 12
Izmir 12
Kunming 12
Montreal 12
Redmond 12
Wuhan 12
Chicago 11
Guadalajara 11
Philadelphia 11
Polska 11
Pune 11
Chengdu 10
Mexico 10
Nanchang 10
Padova 10
Alcalá De Henares 9
Barcelona 9
Brooklyn 9
Fuzhou 9
Hebei 9
Kiel 9
Totale 9.840
Nome #
Is the timing of caloric intake associated with variation in diet-induced thermogenesis and in the metabolic pattern? A randomized cross-over study 2.509
Timing of food intake: sounding the alarm about metabolic impairments? A systematic review. 1.297
Effects of Self-Conditioning Techniques (Self-Hypnosis) in Promoting Weight Loss in Patients with Severe Obesity: A Randomized Controlled Trial 570
Kidney dysfunction and related cardiovascular risk factors among patients with type 2 diabetes 458
Effects of Self-Conditioning Techniques (Self-Hypnosis) in Promoting Weight Loss in Patients with Severe Obesity: A Randomized Controlled Trial 385
Impact of short-term treatment with benzodiazepines and imidazopyridines on glucose metabolism in healthy subjects. 302
Impaired taste sensation in type 2 diabetic patients without chronic complications: a case-control study 264
Ghrelin 216
Predictive role of the Mediterranean diet on mortality in individuals at low cardiovascular risk: A 12-year follow-up population-based cohort study 203
Changes in the gut microbiota composition during pregnancy in patients with gestational diabetes mellitus (GDM) 196
Acute effects of acylated ghrelin on salbutamol-induced metabolic actions in humans 187
The endocrine response to ghrelin as a function of gender in humans in young and elderly subjects. 168
Effects of meal timing on changes in circulating epinephrine, norepinephrine, and acylated ghrelin concentrations: A pilot study 165
The GH-releasing effect of acylated ghrelin in normal subjects is refractory to GH acute auto-feedback but is inhibited after short-term GH administration inducing IGF1 increase 164
Incidence of diabetes mellitus, cardiovascular outcomes and mortality after a 12-month lifestyle intervention: A 9-year follow-up 151
Changes in weight and nutritional habits in adults with obesity during the “lockdown” period caused by the COVID-19 virus emergency 131
Association of kidney disease measures with risk of renal function worsening in patients with type 1 diabetes 11 Medical and Health Sciences 1103 Clinical Sciences 124
Dietary interventions modify the gut microbiota during pregnancy in patients with gestational diabetes mellitus (GDM) 118
Ghrelin secretion is inhibited by glucose load and insulin-induced hypoglycaemia but unaffected by glucagon and arginine in humans 115
Activity of GH/IGF-I axis in patients with dilated cardiomyopathy 113
Circulating ghrelin levels in newborns are not associated to gender, body weight and hormonal parameters but depend on the type of delivery. 105
Testing pituitary function in aging individuals 103
Cortistatin-8, a synthetic cortistatin-derived ghrelin receptor ligand, does not modify the endocrine responses to acylated ghrelin or hexarelin in humans 101
HYPERCORTISOLISM DUE TO CUSHING’S DISEASE IS ASSOCIATED TO DERANGED GHRELIN SECRETION AND ACTION 101
Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans 100
The nutritional status has no major role in the age-related reduction of IGF-I secretion. 100
Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. 99
The metabolic response to the activation ofthe beta-adrenergic receptor by salbutamol is amplified by acylated ghrelin 99
Endocrine and metabolic response to extreme altitude and physical exercise in athletes. 99
Ghrelin and synthetic growth hormone secretagogues are cardioactive molecules with identities and differences 94
MEDIATORI CENTRALI E PERIFERICI DEL COMPORTAMENTO ALIMENTARE 94
The GH response to GHRH in normal adults is not affected by enalapril or furosemide while is blunted by digoxin. 93
Cardiac effects of hexarelin in hypopituitary adults. 92
Sleep abnormalities in type 2 diabetes may be associated with glycemic control 91
Ghrelin: endocrine, metabolic and cardiovascular actions 91
Primary hyperparathyroidism is associated with an impaired secretion of growth hormone but not of the other anterior pituitary hormones. 90
Biologic activities of growth hormone secretagogues in humans. 90
The continuous infusion of acylated ghrelin enhances growth hormone secretion and worsens glucose metabolism in humans 90
ACTIVITY OF GH/IGF-I AXIS IN PATIENTS WITH DILATED CARDIOMYOPATHY 89
Acetylcholine regulates ghrelin secretion in humans 89
Cortistatin-17 and somatostatin-14 display the same effects on growth hormone, prolactin, and insulin secretion in patients with acromegaly or prolactinoma 88
Self-reported adherence to diet and preferences towards type of meal plan in patient with type 2 diabetes mellitus. A cross-sectional study. 88
Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. 87
Activity of GH/IGF-I axis in burn patients: comparison with normal subjects and patients with growth hormone deficiency. 86
GHRELIN SECRETION IS INHIBITED BY GLUCOSE LOAD AND INSULIN-INDUCED HYPOGLYCEMIA BUT UNAFFECTED BY GLUCAGON AND ARGININE IN HUMANS 85
d-Lys-GHRP-6 does not modify the endocrine response to acylated ghrelin or hexarelin in humans 85
CORTICOTROPH AND ADRENAL RESPONSIVENESS TO hCRH, HEXARELIN AND ACTH IN YOUNG AND ELDERLY SUBJECTS 84
Circulating obestatin levels in normal and Type 2 diabetic subjects. 84
Ghrelin: much more than a natural growth hormone secretagogue. 83
Type 2 diabetes mellitus is associated with disruptions as a function of metabolic control. 83
Continuous glucose monitoring is more effective than mixed meal test in the diagnosis of post-gastric bypass reactive hypoglycemia 83
Effect of digoxin on the somatotroph responsiveness to growth hormone-releasing hormone (GHRH) alone or combined with arginine in normal young volunteers. 82
Beta-adrenergic agonism does not impair the GH response to acylated ghrelin inhumans 81
Acetylcholine does not play a major role in mediating the endocrine responses to ghrelin, a natural ligand of the GH secretagogue receptor, in humans. 81
Activity of GH/IGF-I axis in patients with dilated cardiomyopathy. 80
Ghrelin inhibits LH pulsatile secretion in humans. 80
Age-related variations of the GH response to GH secretagogues in humans. 79
Ghrelin, hypothalamus-pituitary-adrenal (HPA) axis and Cushing's syndrome 79
GH-independent cardiotropic activities of hexarelin in patients with severe left ventricular dysfunction due to dilated and ischemic cardiomyopathy. 79
Acylated ghrelin inhibits spontaneous luteinizing hormone pulsatility and responsiveness to naloxone but not that to gonadotropin-releasing hormone in young men: evidence for a central inhibitory action of ghrelin on the gonadal axis 79
BASAL AND STIMULATED GH SECRETION IN CUSHING’S SYNDROME: EFFECTS OF GHRELIN AND GHRH+ARGININE 79
Endocrine and metabolic actions of ghrelin 79
Brain-gut communication: cortistatin, somatostatin and ghrelin 79
Is HDL cholesterol protective in patients with type 2 diabetes? A retrospective population-based cohort study 78
Expression of ghrelin and of the GH secretagogue receptor by pancreatic islet cells and related endocrine tumors 77
EP1572: a novel peptido-mimetic GH secretagogue with potent and selective GH-releasing activity in man. 77
Activity of GH/IGF-I axis in patients with dilated cardiomyopathy 77
Other than Growth Hormone Neuroendocrine Actions of Ghrelin 77
Presence of cortistatin in the human pancreas. 76
WRIST ACTIGRAPHY DOES NOT REVEAL SLEEP DISTURBANCES IN PATIENTS WITH ADDISON’S DISEASE UNDER CONVENTIONAL GLUCOCORTICOID REPLACEMENT THERAPY 76
Tyr-Ala-Hexarelin, a synthetic octapeptide, possesses the same endocrine activities of Hexarelin and GHRP-2 in humans. 75
Effect of desacyl ghrelin, obestatin and related peptides on triglyceride storage, metabolism and GHSR signaling in 3T3-L1 adipocytes 73
Ghrelin and synthetic GH secretagogues. 72
Cardiac effects of hexarelin in hypopituitary adults 72
Metabolic and endocrine effects of physiological increments in plasma ghrelin concentrations 72
Continuous glucose monitoring is more effective than mixed meal test in the diagnosis of post-gastric by pass reactive hypoglycemia 72
Radionuclide angiocardiographic evaluation of the cardiovascular effects of recombinant human IGF-I in normal adults. 71
Myocardial Insulin-like Growth Factor-1 and Insulin-like Growth Factor Binding Protein-3 Gene Expression in Failing Hearts Harvested From Patients Undergoing Cardiac Transplantation 71
AZIONI ENDOCRINE E EXTRA-ENDOCRINE DI GHRELIN E DEI GHS SINTETICI 71
Growth hormone-independent cardiotropic activities of growth hormone-releasing peptides in normal subjects, in patients with growth hormone deficiency, and in patients with idiopathic or ischemic dilated cardiomyopathy. 70
Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans 69
GH secretion is impaired in patients with primary hyperparathyroidism. 69
Cortistatin-17 and -14 exert the same endocrine activities as somatostatin in humans 69
Activity of GH/IGF-I axis in trauma and septic patients during artificial nutrition: different behavior patterns? 69
Endocrine activities of alexamorelin (Ala-His-d-2-methyl-Trp-Ala-Trp-d-Phe-Lys-NH2), a synthetic GH secretagogue, in humans 69
Ghrelin secretion is inhibited by either somatostatin or cortistatin in humans. 69
Ormoni dell’ipofisi posteriore 69
METABOLIC MODULATION OF GHRELIN SECRETION IN HUMANS 69
In Patients with Obesity, Are Affective Temperaments Associated with Attrition? An Evaluation during and before the SARS-CoV-2 Pandemic 69
Ghrelin: a new hormone with endocrine and non-endocrine activities 68
EFFECTS OF CORTISTATIN-17 AND SOMATOSTATIN-14 ON ACTH AND CORTISOL HYPERSECRETION IN PATIENTS WITH CUSHING’S DISEASE 67
A New Clinical Model to Estimate the Pre-Test Probability of Cushing's Syndrome: The Cushing Score 67
H9c2 cardiac muscle cells express insulin-like growth factor binding protein-3 (IGFBP-3). 66
Effects of glucose, free fatty acids or arginine load on the GH-releasing activity of ghrelin in humans. 66
Known and unknown growth hormone secretagogue receptors and their ligands 65
Ghrelin exerts an inhibitory modulation on LH pulsatility in humans. 65
Ghrelin and anterior pituitary function 65
Ghrelin and other gastrointestinal peptides involved in the control of food intake 65
Hexarelin, a synthetic growth-hormone releasing peptide, shows no interaction with corticotropin-releasing hormone and vasopressin on adrenocorticotropin and cortisol secretion in humans. 64
Age-related variations in the neuroendocrine control, more than impaired receptor sensitivity, cause the reduction in the GH-releasing activity of GHRPs in human aging. 64
Totale 14.239
Categoria #
all - tutte 53.639
article - articoli 0
book - libri 0
conference - conferenze 4.455
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 58.094


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.703 0 0 0 0 0 482 299 155 241 211 199 116
2020/20212.383 194 130 220 118 278 121 231 121 288 297 148 237
2021/20222.066 77 100 119 125 146 114 147 120 84 189 338 507
2022/20232.990 335 226 54 276 288 734 276 229 277 69 135 91
2023/20241.341 174 233 98 85 91 129 59 75 23 69 118 187
2024/20252.034 72 319 159 396 970 118 0 0 0 0 0 0
Totale 19.189